Chemically Programmable and Switchable CAR-T Therapy

被引:35
|
作者
Qi, Junpeng [1 ]
Tsuji, Kohei [2 ,3 ]
Hymel, David [2 ]
Burke, Terrence R., Jr. [2 ]
Hudecek, Michael [4 ]
Rader, Christoph [1 ]
Peng, Haiyong [1 ]
机构
[1] Scripps Res Inst, Dept Immunol & Microbiol, 130 Scripps Way, Jupiter, FL 33458 USA
[2] NCI, Biol Chem Lab, Ctr Canc Res, NIH, Bldg 376 Boyles St, Frederick, MD 21702 USA
[3] Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Dept Med Chem, Chiyoda Ku, 2-3-10 Kandasurugadai, Tokyo 1010062, Japan
[4] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Oberdurrbacherstr 6, D-97080 Wurzburg, Germany
基金
美国国家卫生研究院;
关键词
antibodies; antitumor agents; cell-surface receptors; CAR-Ts; immunotherapy; BISPECIFIC ANTIBODIES; ALDOLASE ANTIBODY; FOLATE RECEPTOR; CELLS; IMMUNOTHERAPY; MOLECULES; SELECTION; STRATEGY;
D O I
10.1002/anie.202005432
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Although macromolecules on cell surfaces are predominantly targeted and drugged with antibodies, they harbor pockets that are only accessible to small molecules and constitutes a rich subset of binding sites with immense potential diagnostic and therapeutic utility. Compared to antibodies, however, small molecules are disadvantaged by a less confined biodistribution, shorter circulatory half-life, and inability to communicate with the immune system. Presented herein is a method that endows small molecules with the ability to recruit and activate chimeric antigen receptor T cells (CAR-Ts). It is based on a CAR-T platform that uses a chemically programmed antibody fragment (cp-Fab) as on/off switch. In proof-of-concept studies, this cp-Fab/CAR-T system targeting folate binding proteins on the cell surface mediated potent and specific eradication of folate-receptor-expressing cancer cells in vitro and in vivo.
引用
收藏
页码:12178 / 12185
页数:8
相关论文
共 50 条
  • [41] CAR-T Cell Therapy: Challenges and Optimization
    Luo, Mei
    Zhang, Hongchang
    Zhu, Linnan
    Xu, Qumiao
    Gao, Qianqian
    CRITICAL REVIEWS IN IMMUNOLOGY, 2021, 41 (01) : 77 - 87
  • [42] The Promise and Challenges of CAR-T Gene Therapy
    Kuehn, Bridget M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (22): : 2167 - 2169
  • [43] Modelling CAR-T therapy in humanized mice
    Wu, Yongxia
    Yu, Xue-Zhong
    EBIOMEDICINE, 2019, 40 : 25 - 26
  • [44] A Theranostic Approach for CAR-T Cell Therapy
    Weber, Wolfgang A.
    Varasteh, Zohreh
    Fritschle, Katja
    Morath, Volker
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5241 - 5243
  • [45] Reactions Related to CAR-T Cell Therapy
    Miao, Lele
    Zhang, Zhengchao
    Ren, Zhijian
    Li, Yumin
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [46] Updates research for CAR-T therapy in China
    Li, Zonghai
    ANNALS OF ONCOLOGY, 2021, 32 : S233 - S233
  • [47] New development in CAR-T cell therapy
    Wang, Zhenguang
    Wu, Zhiqiang
    Liu, Yang
    Han, Weidong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [48] New development in CAR-T cell therapy
    Zhenguang Wang
    Zhiqiang Wu
    Yang Liu
    Weidong Han
    Journal of Hematology & Oncology, 10
  • [49] CAR-T therapy for leukemia: progress and challenges
    Wang, Xin
    Xiao, Qing
    Wang, Zhe
    Feng, Wen-Li
    TRANSLATIONAL RESEARCH, 2017, 182 : 135 - 144
  • [50] Current status and perspectives on CAR-T therapy
    Kim, Ji Woong
    Lee, Sukmook
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2021, 26 (12): : 1393 - 1395